Kissei Pharmaceutical Co., Ltd. (TYO:4547)

Kissei Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	91,695	88,330	75,579	67,493	65,381	69,044
Revenue Growth (YoY)	13.11%	16.87%	11.98%	3.23%	-5.30%	9.19%
Cost of Revenue	46,340	44,265	38,238	35,118	34,143	36,321
Gross Profit	45,355	44,065	37,341	32,375	31,238	32,723
Selling, General & Admin	32,088	22,179	20,790	20,289	19,923	19,607
Research & Development	12,889	12,889	9,474	10,391	10,363	9,626
Other Operating Expenses	129	129	143	149	137	149
Operating Expenses	48,200	38,291	33,324	33,518	32,640	31,217
Operating Income	-2,845	5,774	4,017	-1,143	-1,402	1,506
Interest Expense	-25	-21	-18	-20	-23	-23
Interest & Investment Income	1,618	1,449	1,318	1,402	1,586	1,272
Currency Exchange Gain (Loss)	-164	-229	-103	186	-60	-130
Other Non Operating Income (Expenses)	42	29	35	57	280	131
EBT Excluding Unusual Items	-1,374	7,002	5,249	482	381	2,756
Gain (Loss) on Sale of Investments	21,817	11,719	9,119	13,133	16,161	4,727
Gain (Loss) on Sale of Assets	-184	-215	80	63	-35	-10
Asset Writedown	-2,767	-2,895	-	-	-	-
Other Unusual Items	369	-2	-1	1	-1	3
Pretax Income	17,861	15,609	14,447	13,679	16,506	7,476
Income Tax Expense	3,260	3,634	3,159	3,046	3,475	2,098
Earnings From Continuing Operations	14,601	11,975	11,288	10,633	13,031	5,378
Minority Interest in Earnings	-105	-14	-128	-105	-110	-93
Net Income	14,496	11,961	11,160	10,528	12,921	5,285
Net Income to Common	14,496	11,961	11,160	10,528	12,921	5,285
Net Income Growth	35.09%	7.18%	6.00%	-18.52%	144.48%	87.61%
Shares Outstanding (Basic)	42	44	45	46	46	47
Shares Outstanding (Diluted)	42	44	45	46	46	47
Shares Change (YoY)	-4.61%	-3.62%	-1.86%	-	-1.18%	-0.11%
EPS (Basic)	342.25	274.20	246.58	228.30	280.19	113.25
EPS (Diluted)	342.25	274.20	246.58	228.30	280.19	113.25
EPS Growth	41.61%	11.20%	8.01%	-18.52%	147.41%	87.81%
Free Cash Flow	6,322	2,014	-2,878	-8,782	44	-3,473
Free Cash Flow Per Share	149.26	46.17	-63.59	-190.44	0.95	-74.42
Dividend Per Share	115.000	100.000	82.000	80.000	56.000	54.000
Dividend Growth	33.72%	21.95%	2.50%	42.86%	3.70%	3.85%
Gross Margin	49.46%	49.89%	49.41%	47.97%	47.78%	47.39%
Operating Margin	-3.10%	6.54%	5.32%	-1.69%	-2.14%	2.18%
Profit Margin	15.81%	13.54%	14.77%	15.60%	19.76%	7.66%
Free Cash Flow Margin	6.89%	2.28%	-3.81%	-13.01%	0.07%	-5.03%
EBITDA	1,742	10,389	8,271	2,966	2,328	4,654
EBITDA Margin	1.90%	11.76%	10.94%	4.40%	3.56%	6.74%
D&A For EBITDA	4,587	4,615	4,254	4,109	3,730	3,148
EBIT	-2,845	5,774	4,017	-1,143	-1,402	1,506
EBIT Margin	-3.10%	6.54%	5.32%	-1.69%	-2.14%	2.18%
Effective Tax Rate	18.25%	23.28%	21.87%	22.27%	21.05%	28.06%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.